GNG13 (G protein subunit gamma 13) functions as a crucial component of heterotrimeric G-protein complexes, where it works with beta subunits to enable GTPase activity, GDP-GTP exchange, and G protein-effector interactions in transmembrane signaling systems 1. The protein exhibits tissue-specific roles and differential expression patterns across various pathological conditions. In cancer contexts, GNG13 shows complex and contradictory expression patterns: it is downregulated in epithelial ovarian cancer and breast cancer, where low expression correlates with poor prognosis, advanced tumor stage, and metastasis 1, while it is upregulated in gastrointestinal stromal tumors (GIST), where high expression associates with larger tumor size, higher mitotic index, and poor prognosis 2. In neurological contexts, GNG13 serves as a potential biomarker for Purkinje cell health in the cerebellum, with expression levels significantly reduced in Alzheimer's disease patients compared to healthy controls 3. The gene also plays roles in hematopoietic stem cell proliferation 4, keloid formation through G protein-coupled receptor signaling pathways 5, and osteoporosis as a hub protein in disease networks 6. These diverse roles suggest GNG13 functions as a critical signaling mediator with context-dependent effects on cellular behavior and disease progression.